Don't want emails from us anymore? Click here to unsubscribe.
Hello!
New Alert: CERo Therapeutics Holdings, Inc. (NASDAQ: CERO)
CERO is our brand new NASDAQ alert with high gain potential.
CERO has been trending higher recently and has experienced some increased upside volatility.
Now, its approaching what could be a big breakout opportunity.
CERO is forming a chart setup that in the past has resulted in some of our biggest winners.
In addition, the company announced multiple big accomplishments recently.
CERO is a NASDAQ listed biotech company.
CERO is an "innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer".
CERO's "proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy".
As the company further explains:
"This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T")."
CERO "believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors".
CERO "anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies as well as for certain solid tumors".
The company "is currently initiating its first-in-human, multi-center, open-label, Phase 1/1b study designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory, has measurable residual disease, or has a mutation of the TP53 gene."
As the company further notes:
"The two-part study will begin with dose escalation to determine the highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to evaluate safety and efficacy."
"Primary outcome measures include the incidence of adverse events (AEs) and serious adverse events (SAEs), the incidence of dose-limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK)."
CERO has announced multiple accomplishments that could be additional growth catalysts.
On March 31, the company announced:
"CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors"
Here are the company's comments from this press release:
"CERo Chief Medical Officer Robert Sikorski, M.D., Ph.D. commented, "Following the launch of our AML trial, we are now starting a second clinical study of CER-1236 to evaluate its potential in solid tumors and bring new therapeutic options to patients with ovarian and lung cancer," said Robert Sikorski, M.D., Ph.D., Chief Medical Officer of CERo. "CER-1236 is novel: the first CAR-T cell therapy to target Tim-4L and the first with phagocytic activity programmed into a T cell. Preclinical data suggest that this dual mechanism may help overcome key resistance barriers that have hampered solid tumor CAR-T trials. The FDA's collaborative role has been critical to maintaining development velocity and enabling us to operate two open trials in both hematologic and solid tumors. Taken together, this expansion reflects our belief in the therapeutic breadth and the commercial and partnering potential of CER-1236.""
Earlier this month, the company announced:
"CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236"
- "Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families"
Last week, the company announced:
"CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing"
As the company explains:
"The gross proceeds to CERo from the offering are expected to be up to $8 million, including $5 million expected to be received through the investment of securities at the first closing, and up to $3 million of cash that may be funded at one or more additional closings, at the election of the investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. The proceeds will also help to address current Nasdaq deficiencies around Shareholders Equity and extend cash on hand to maintain operations and extend runway."
On Thursday, the company announced:
"CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia"
Here are some of the comments from this press release:
"Dr. Yazan Migdady, Co-Director, Research and Clinical Innovation for the Myeloid Disease & Allogeneic Stem Cell Program at Colorado Blood Cancer Institute, an investigator in the trial, commented, "The use of chimeric engulfment receptor technology in cellular therapy for AML offers new hope for patients battling aggressive leukemia. This trial represents a crucial step forward in developing innovative therapies, enhancing patient clinical and survival outcomes by improving treatment efficacy, reducing relapse rates, and ultimately bringing a brighter future to AML patients and their families."
In addition:
"Chris Ehrlich, CERo Therapeutics CEO added, "CBCI is a world-renowned cancer center, and we believe their participation in our AML trial is continued validation of the scientific work performed to date with CER-1236. We look forward to announcing enrollment and initial dosing in the near term for this trial and to progress in launching our solid tumor study.""
On Friday, the company announced:
- "CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting"
CERO could be positioned for increased growth.
Make sure to do your own due diligence.
Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, PR10, Website, Chart
Happy Trading!
UltimateStockAlerts
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
